The LILAC – TIMI 76 Trial, an Anticoagulant (Blood Thinner) Study, is Now Enrolling Afib Patients
- Summary: The LILAC – TIMI 76 Trial, an anticoagulant (blood thinner) study, is now enrolling afib patients
- Reading time: 1–2 minutes
A new clinical trial is enrolling afib patients who, because of your doctor’s decision or your preference, are not currently taking an anticoagulant (blood thinner) to reduce the risk of clots and stroke.
- The LILAC – TIMI 76 trial will evaluate a monthly medication from a new class of anticoagulants.
- This clinical trial is recruiting afib patients who are age 65 years or over and are not appropriate for currently available blood thinners (as determined by your doctor).
- If you have afib but have never taken a blood thinner, or stopped taking a blood thinner more than 60 days ago, you may be eligible to participate.
- An initial screening period with tests, assessments, and questionnaires will be done to determine if this trial is right for you. The trial is expected to last for about 18 months (1 1/2 years) for each participant.
To learn more and find information to discuss with your doctor, please view the: